Canandaigua National Bank & Trust’s AstraZeneca AZN Stock Holding History

Canandaigua National Bank & Trust’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.84M	Buy	+11,271	New	+$1.88M	0.16%	124
2025 Q4	$2.03M	Buy	11,040 +741	+7%	+$130K	0.18%	116
2025 Q3	$1.58M	Buy	10,299 +397	+4%	+$60.1K	0.14%	144
2025 Q2	$1.38M	Buy	9,902 +1,630	+20%	+$228K	0.13%	155
2025 Q1	$1.22M	Buy	8,272 +862	+12%	+$125K	0.12%	164
2024 Q4	$971K	Sell	7,410 -47	-0.6%	-$6.58K	0.1%	181
2024 Q3	$1.16M	Sell	7,457 -413	-5%	-$66.7K	0.11%	171
2024 Q2	$1.23M	Sell	7,870 -146	-2%	-$22K	0.13%	146
2024 Q1	$1.09M	Buy	+8,016	New	+$1.06M	0.16%	133
2018 Q3	–	Sell	-3,974	Closed	-$279K	–	346
2018 Q2	$279K	Buy	3,974 +57	+1%	+$4.1K	0.05%	249
2018 Q1	$274K	Buy	+3,917	New	+$271K	0.04%	299

Other funds holding AZN

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return

PAS

Professional Advisory Services Vero Beach, Florida $837M AUM 20.44% 1-Year Est. Return

Gradient Investments Arden Hills, Minnesota $7B AUM 14.85% 1-Year Est. Return

PNC

Park National Corp Newark, Ohio $3.69B AUM 18.32% 1-Year Est. Return

CCM

Cox Capital Management Andover, Massachusetts $179M AUM 28.94% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return

Parrish Capital Kennesaw, Georgia $103M AUM 35.11% 1-Year Est. Return

Sapient Capital Indianapolis, Indiana $7.44B AUM 23.27% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Canandaigua National Bank & Trust's AZN Position: Q3 2026 in Review

Canandaigua National Bank & Trust opened a new position in AstraZeneca (AZN) in Q3 2026: 11,271 shares worth $1.84M. The stake represents 0.16% of the portfolio and ranks #124 among its holdings. This is a return to the name: Canandaigua National Bank & Trust previously reported a position in AZN as recently as Q4 2025.

Canandaigua National Bank & Trust first reported a position in AZN in Q1 2018 and has held it in 11 quarters since. The position peaked at $2.03M in Q4 2025. 47 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

Canandaigua National Bank & Trust held 11,271 shares of AstraZeneca worth $1.84M as of Q3 2026.
AstraZeneca was a new Canandaigua National Bank & Trust position in Q3 2026.
AstraZeneca made up 0.16% of Canandaigua National Bank & Trust's portfolio in Q3 2026, its #124 holding.
Canandaigua National Bank & Trust first reported a position in AstraZeneca in Q1 2018 and has held it in 11 quarters since.
Canandaigua National Bank & Trust's AstraZeneca position peaked at $2.03M in Q4 2025.
47 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Canandaigua National Bank & Trust's 13F filing for Q3 2026, filed 7 Oct 2026.